Search

Displaying results 4101 - 4110 of 10000 in total
  1. Drug

    SNS-314

    go.drugbank.com/drugs/DB06134
    Investigational

    SNS-314 inhibits tumor growth in a variety of preclinical models, and it is now being tested in single agent Phase 1 studies in patients with advanced solid tumours.

  2. Drug

    Methylpropylpropanediol dinitrate

    go.drugbank.com/drugs/DB13408
    Experimental

    Categories: Vasodilators Used in Cardiac Diseases
  3. Drug

    IMC-1C11

    go.drugbank.com/drugs/DB06101
    Experimental

    IMC-1C11 is an anti-angiogenesis agent.

  4. Drug

    CTCE-0214

    go.drugbank.com/drugs/DB05934
    Experimental

    CTCE-0214 is a stable peptide agonist of stromal cell-derived factor-1 (SDF-1), a key signaling molecule in the proliferation, homing, engraftment and expansion of hematopoietic stem cells and white blood

  5. Drug

    Neosaxitoxin

    go.drugbank.com/drugs/DB12989
    Investigational

    Neosaxitoxin is under investigation in clinical trial NCT01786655 (Safety Study of Long-Acting Local Anesthetic).

    Categories: Compounds used in a research, industrial, or household setting
  6. Drug

    Gallium maltolate

    go.drugbank.com/drugs/DB05420
    Investigational

    Gallium maltolate is Titan’s novel oral agent in development for the potential treatment of chronic bacterial infections, bone disease and cancer.

  7. Drug

    ENMD-1198

    go.drugbank.com/drugs/DB05959
    Experimental

  8. Drug

    VX-148

    go.drugbank.com/drugs/DB06103
    Experimental

    The IMPDH enzyme plays a key role in regulating immune response and proliferation of specific cell types, including lymphocytes. VX-148 is a developed for the treatment of autoimmune diseases.

  9. Drug

    Ibutilide

    go.drugbank.com/drugs/DB00308
    Approved

    Ibutilide is a Class III antiarrhythmic agent available in intravenous formulations.

    Synonyms: N-(4-{4-[ethyl(heptyl)amino]-1-hydroxybutyl}phenyl)methanesulfonamide
  10. Drug

    19-norandrostenedione

    go.drugbank.com/drugs/DB01434
    ExperimentalIllicit

    After 2005, 19-Norandrostenedione was regulated in the United States as a schedule III controlled substance, as well as banned from use in competitive sports by the World Anti-Doping Agency. … In the body 19-norandrostenedione is rapidly metabolized into [nandrolone], also known as nortestosterone.